RESEARCH INTERESTS

Dr. Mei’s laboratory focuses on the development of lipid nanoparticle (LNP)-based gene delivery systems for RNA therapeutics, with applications in both immunostimulation (e.g., cancer preventive and therapeutic vaccines) and immunomodulation (e.g., inducing immune tolerance to therapeutic viral vectors, autoantigens, allergens, therapeutic transgenes, and proteins). His research integrates molecular pharmaceutics, immunoengineering, and translational pharmaceutical sciences to enable novel chemoimmunotherapy, gene therapy, and cell therapy approaches.

Additionally, his lab investigates how immunometabolic cues, such as IFN-γ and amino acid deprivation, influence mRNA delivery and translation, and the downstream impact on innate and adaptive immunity. A combination of chemical synthesis, formulation development, high-throughput screening, and in vitro-in vivo disease modeling is used to advance next-generation precision immunotherapies.

Research Interest Keywords
mRNA therapeutics; lipid nanoparticles (LNPs); liposomes, RNA delivery; cancer immunotherapy; immune tolerance; dendritic cells; macrophages, hepatocytes, immunometabolism; gene delivery; nanomedicine; CAR T cell therapy; AAV immunogenicity; immunoengineering; tolerogenic vaccines

GRANTS

  • EXTERNAL GRANT OR CONTRACT
    FEATURED
    Featured
    COMPLEMENTARY BIOTHERAPEUTIC DELIVERY PLATFORMS FOR ENABLING GENE RE-DELIVERY
    NIH NATIONAL INST OF GENERAL MEDICAL SCI1 Aug 2024
    NIH NATIONAL INST OF GENERAL MEDICAL SCI
  • EXTERNAL GRANT OR CONTRACT
    COMPLEMENTARY BIOTHERAPEUTIC DELIVERY PLATFORMS FOR ENABLING GENE RE-DELIVERY
    1 Aug 2025 - 31 May 2029